Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Evercore ISI analyst Umer Raffat maintained a Buy rating on Organon (OGN – Research Report) today. The company’s shares opened ...